All In MedTech

Device Trial Radar · NCT07207122

Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 8, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Sanmai Technologies PBC dba SanmaiNot on our public-company list
Sponsor type
Industry
First posted
Oct 3, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 22 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a pilot randomized, sham-controlled, double-blind, multi-center study evaluating the safety and preliminary effectiveness of the Gen0Bh Transcranial Focused Ultrasound System for the treatment of motor symptoms in individuals with idiopathic Parkinson's disease.

Conditions

  • Parkinson Disease

Interventions

  • Gen0Bh Transcranial Focused Ultrasound System (Active)Device

    The investigational Gen0Bh system delivers noninvasive, transcranial focused ultrasound to modulate neural activity in the bilateral globus pallidus. Stimulation parameters, including frequency, intensity, and duty cycle, are pre-specified and controlled by the device software. Treatments are administered by trained study personnel in a clinical setting over 20 sessions across approximately 4 to 6 weeks.

  • Gen0Bh Transcranial Focused Ultrasound System (Sham)Device

    The sham configuration uses the same device platform and mimics all procedural aspects of active treatment, including acoustic coupling, device setup, and session duration, without delivering therapeutic ultrasound energy to the target region. This approach is designed to maintain participant and assessor blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in MDS-UPDRS Part III Total Score (OFF Medication State)Time frame: Baseline up to 6 weeks
  2. Incidence of Serious Adverse Device Events (SADEs)Time frame: Baseline up to 6 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona · Recruiting

  • The Regenesis Project

    Santa Monica, California · Recruiting

  • UF - McKnight Brain Institute

    Gainesville, Florida · Recruiting

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.